| Title |
The role of mirtazapine in patients with fibromyalgia: a systematic review
|
|---|---|
| Published in |
Rheumatology International, June 2018
|
| DOI | 10.1007/s00296-018-4068-3 |
| Pubmed ID | |
| Authors |
Andreina A. Ottman, Carly B. Warner, Jamie N. Brown |
| Abstract |
Mirtazapine is commonly used to treat major depressive disorder. Due to its effects on multiple neurotransmitters, it has been investigated for possible benefits in patients with fibromyalgia. The objective of this systematic review is to assess the efficacy and safety of mirtazapine in the treatment of patients with fibromyalgia. Pubmed (1946-May 2018), Embase (1947-May 2018), CENTRAL, and ClinicalTrials.gov were queried using the search term combination: fibromyalgia, pain, chronic pain, neuralgia, neuropathic pain, chronic widespread pain, or chronic pain syndrome and mirtazapine. Studies appropriate to the objective were evaluated, including three randomized, placebo-controlled trials and one open-label trial, investigating the effect of mirtazapine in patients with fibromyalgia. In patients with fibromyalgia, treatment with mirtazapine resulted in improvements in pain, sleep, and quality of life. Study durations ranged from 6 to 13 weeks and studies used varying dosing strategies for mirtazapine. Minor occurrences of somnolence, weight gain, nasopharyngitis, dry mouth, and increased appetite were reported with mirtazapine use. Based on the reviewed literature, mirtazapine appears to be a promising therapy to improve pain, sleep, and quality of life in patients with fibromyalgia. These benefits were demonstrated in patients that were treatment naïve and those that had failed previous therapies. Additional clinical evidence through larger and longer length trials would be of benefit to further define the role of mirtazapine for patients with fibromyalgia. |
X Demographics
The data shown below were collected from the profiles of 15 X users who shared this research output. Click here to find out more about how the information was compiled.
Geographical breakdown
| Country | Count | As % |
|---|---|---|
| United Kingdom | 3 | 20% |
| Australia | 3 | 20% |
| United States | 2 | 13% |
| Japan | 1 | 7% |
| Singapore | 1 | 7% |
| Unknown | 5 | 33% |
Demographic breakdown
| Type | Count | As % |
|---|---|---|
| Members of the public | 11 | 73% |
| Scientists | 3 | 20% |
| Practitioners (doctors, other healthcare professionals) | 1 | 7% |
Mendeley readers
The data shown below were compiled from readership statistics for 81 Mendeley readers of this research output. Click here to see the associated Mendeley record.
Geographical breakdown
| Country | Count | As % |
|---|---|---|
| Unknown | 81 | 100% |
Demographic breakdown
| Readers by professional status | Count | As % |
|---|---|---|
| Student > Bachelor | 15 | 19% |
| Student > Master | 11 | 14% |
| Researcher | 9 | 11% |
| Student > Doctoral Student | 6 | 7% |
| Student > Postgraduate | 4 | 5% |
| Other | 9 | 11% |
| Unknown | 27 | 33% |
| Readers by discipline | Count | As % |
|---|---|---|
| Medicine and Dentistry | 27 | 33% |
| Nursing and Health Professions | 8 | 10% |
| Psychology | 6 | 7% |
| Pharmacology, Toxicology and Pharmaceutical Science | 3 | 4% |
| Sports and Recreations | 3 | 4% |
| Other | 5 | 6% |
| Unknown | 29 | 36% |
Attention Score in Context
This research output has an Altmetric Attention Score of 19. This is our high-level measure of the quality and quantity of online attention that it has received. This Attention Score, as well as the ranking and number of research outputs shown below, was calculated when the research output was last mentioned on 06 April 2021.
All research outputs
#1,692,190
of 23,314,015 outputs
Outputs from Rheumatology International
#98
of 2,232 outputs
Outputs of similar age
#38,164
of 330,542 outputs
Outputs of similar age from Rheumatology International
#3
of 35 outputs
Altmetric has tracked 23,314,015 research outputs across all sources so far. Compared to these this one has done particularly well and is in the 92nd percentile: it's in the top 10% of all research outputs ever tracked by Altmetric.
So far Altmetric has tracked 2,232 research outputs from this source. They typically receive a little more attention than average, with a mean Attention Score of 5.6. This one has done particularly well, scoring higher than 95% of its peers.
Older research outputs will score higher simply because they've had more time to accumulate mentions. To account for age we can compare this Altmetric Attention Score to the 330,542 tracked outputs that were published within six weeks on either side of this one in any source. This one has done well, scoring higher than 88% of its contemporaries.
We're also able to compare this research output to 35 others from the same source and published within six weeks on either side of this one. This one has done particularly well, scoring higher than 94% of its contemporaries.